<DOC>
	<DOCNO>NCT02689362</DOCNO>
	<brief_summary>This phase II , multicenter , randomize , double-blind , double-dummy study four parallel treatment group , active control , perform Brazilian study site sponsorship Eurofarma Laboratórios S.A.. The enrollment participant study start relevant ethical regulatory approval estimate duration 18 month . One hundred forty-four participant T2DM accord criterion ADA consent participation study signing Informed Consent Form ( ICF ) enrol study . In order enrol , patient must meet inclusion criterion none exclusion criterion . The eligible participant randomize 1:1:1:1 receive evogliptin ( EVO ) dose 2.5 mg/day ( N = 36 ) , 5.0 mg/day ( N = 36 ) 10 mg/day ( N = 36 ) sitagliptin ( SITA ) dose 100 mg/day ( N = 36 ) , single daily dose , 12 week .</brief_summary>
	<brief_title>Evogliptin Type 2 Diabetes Mellitus ( EVOLUTION : EVOgLiptina Diabetes Mellitus TIpO 2 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Male female patient meet follow criterion enrol study : 1 . Aged 20 75 year old . 2 . Diagnosis T2DM accord criterion American Diabetes Association ( ADA ) . 3 . Not receive treatment oral hypoglycemic agent insulin within 12 week prior screen visit ; 4 . Glycated hemoglobin ( HbA1c ) level screen visit 7.5 % ≤ HbA1c ≤ 10.5 % , appropriate treatment diet physical exercise ≥ 12 week ; 5 . Body mass index ( BMI ) 20 kg/m2 ≤ BMI ≤ 40 kg/m2 screen visit . 6 . Signing Informed Consent Form ( ICF ) performance study procedure . Patients meet least one follow criterion exclude study : 1 . Fasting blood glucose value &gt; 300 mg/dL severe clinical manifestation present ( significant loss weight , severe symptom and/or ketonuria ) . 2 . Current participation weight loss program , without antiobesity drug use . 3 . Presence heart failure functional class III IV accord New York Heart Association ( NYHA ) . 4 . Presence symptomatic liver gall bladder disease . 5 . History myocardial infarction , transient ischemic attack coronary angioplasty within 6 month prior screen visit . 6 . History gastrointestinal resection . 7 . Estimated creatinine clearance ( Cockroft Gault formula ) &lt; 60 mL/min . 8 . Serum ALT and/or AST level ≥ 2.5 x upper normal limit . 9 . Serum CPK level ≥ 3 x upper normal limit . 10 . Fasting triglyceride &gt; 400 mg/dL . 11 . History major skin allergy . 12 . Use corticosteroid within 3 month prior screen visit . 13 . Concomitant treatment warfarin , dicoumarinic agent digoxin . 14 . Concomitant use drug food interfere CYP3A4 pathway liver metabolism include , limited : Inhibitors : antibacterial agent ( erythromycin ) , antifungal ( itraconazole , ketoconazole ) , antiviral ( ritonavir , saquinavir , amprenavir , indinavir , nelfinavir ) , H2 receptor antagonist ( cimetidine ) grapefruit juice ; Inducers : dexamethasone , rifampin anticonvulsant ( phenytoin , phenobarbital , carbamazepine ) 15 . History untreated uncontrolled thyroid disorder . 16 . History drug abuse moderate/heavy alcohol consumption within 2 month prior screen . 17 . Presence severe uncontrolled disease . 18 . Presence pregnancy breastfeed . 19 . Women childbearing potential agree use proven effective contraceptive method , unless surgically sterile declare expressly exempt pregnancy risk engage sexual practice engage nonreproductive manner . 20 . Participation clinical trial protocol within previous 12 month unless , investigator 's discretion , participation may imply direct benefit participant . 21 . Presence condition , investigator 's discretion , may render patient inadequate study participation .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Diabetes Mellitus Type 2</keyword>
</DOC>